Metastatic melanoma

This phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-co…

Researchers are testing whether adding the chemotherapy drug irinotecan to the immunotherapy pembrolizumab helps people with metastatic or recurrent melanoma that cannot be removed by surgery. The trial enrolls adults whose cancer has returned at least six months after adjuvant p…

Researchers are testing whether adding an experimental DNA vaccine called iSCIB1+ to standard immunotherapy drugs nivolumab and ipilimumab helps people with advanced melanoma that cannot be removed by surgery. About 550 participants will be randomly assigned to receive either the…

Researchers are testing a treatment for melanoma that has spread to the liver. They collect tumor-infiltrating lymphocytes, a type of immune cell, from the patient's own tumor and grow them in the lab. Before returning the cells, they use a technique called percutaneous hepatic p…

This early-stage trial tests whether immune cells taken from a patient's own tumor (TIL) can be safely given directly into the liver or through a vein to fight metastatic melanoma. 18 adults with advanced uveal or cutaneous melanoma that has spread will receive TIL along with che…

This study tests a combination of two immunotherapy drugs, nivolumab and relatlimab, in people with advanced melanoma that hasn't been treated before. The goal is to see if the combination is safe and helps shrink tumors. About 30 adults and teens (ages 12 and up) in India will t…

This phase 2 trial is investigating whether giving immunotherapy before surgery for advanced melanoma (stage IIIB to IV M1a) can maintain survival while allowing patients to skip the usual adjuvant therapy after surgery. Participants are randomly assigned to receive either two in…

This trial investigates whether a sensitive blood test (Signatera) can detect when it is safe to pause immunotherapy in people with advanced solid tumors like lung cancer, melanoma, and colorectal cancer. Participants are randomly assigned to either continuous standard immunother…

This study tests a new drug, prifetrastat, combined with fulvestrant for people with advanced HR+/HER2- breast cancer that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. About 51 participants will receive the combination to see if it can shrink tumors o…

This study looks at whether giving immunotherapy infusions in the morning improves outcomes for people with advanced melanoma. Researchers will compare morning versus afternoon/evening dosing in 108 participants. The goal is to see if aligning treatment with the body's natural im…

This pilot study explores whether a special PET/CT scan that tracks CD8 immune cells can help select the best tumors for harvesting immune cells (TILs) to treat stage IV melanoma. Participants receive the TIL therapy lifileucel (AMTAGVI) after a chemotherapy regimen. The goal is …

This study tests whether adding axelopran, a drug that blocks opioid side effects in the gut, to the immunotherapy nivolumab can help people with advanced melanoma that no longer responds to PD-1 inhibitors. The trial includes about 28 adults with unresectable or metastatic cutan…

This study tests an experimental drug, TAX2, in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in more people. Researchers will monitor side effects, h…

This study tests a therapy called Perkileucel, made from a patient's own immune cells (tumor-infiltrating lymphocytes). These cells are collected from a surgically removed melanoma tumor, grown in a lab, and then infused back into the patient. Before the infusion, patients receiv…

This study tests whether giving a Pfizer-BioNTech COVID-19 mRNA vaccine before standard immunotherapy (pembrolizumab) and chemotherapy can improve outcomes for people with stage 4 non-small cell lung cancer. Researchers will enroll 500 adults to see if the vaccine helps the immun…

This study tests a treatment called extracorporeal photopheresis (ECP) for people with advanced melanoma who develop severe colitis or hepatitis from immunotherapy. ECP filters a patient's blood, treats it with a light-activated drug, and returns it to the body. The trial compare…

This early-phase trial tests a virus called DNX-2401, designed to infect and destroy melanoma cells in the brain and body. About 50 adults with stage IV melanoma will receive injections to find the safest dose and number of treatments. The main goal is to check for side effects, …

This early study tests a new treatment for advanced skin melanoma that has not responded to standard therapies. Ten participants will receive two injections of gold nanorods directly into their tumors, which are then activated with a special light to generate heat and destroy can…

This Phase 2 trial tests a new cell therapy called RAPA-201 for people with advanced melanoma that has stopped responding to PD-(L)1 inhibitors. The therapy uses a patient's own immune cells, modified to resist the drug rapamycin, and is given along with chemotherapy. The study a…

This Phase 2 trial tests whether a personalized cell therapy called HS-IT101 works better than chemotherapy for people with advanced melanoma that has stopped responding to standard treatments. HS-IT101 uses a patient's own immune cells, grown in large numbers in a lab, to fight …

This study tests whether a new MRI contrast agent, gadopiclenol, can detect brain metastases earlier than standard methods in 180 patients with advanced lung, breast, or skin cancer. Participants will receive screening brain MRIs to compare diagnosis timing and accuracy. The goal…

This study tests a new PET imaging agent, 68Ga-cPP-BCH, to detect PD-L1 protein levels in tumors of people with lung cancer, melanoma, or other solid tumors. The goal is to see if this scan can identify who might benefit from anti-PD-1/PD-L1 immunotherapy without needing a tissue…

Researchers are testing whether a single high dose of psilocybin, given alongside a structured talking therapy called PEARL, reduces depressive symptoms in adults with advanced cancer. The trial enrolls 46 people in Ontario with stage IV solid tumors, sarcoma, melanoma, endocrine…

This study looks at whether intermittent fasting is safe and doable for people with advanced solid tumors who are starting immunotherapy. About 90 participants will be split into three groups: no fasting, eating only during an 8-hour window each day, or fasting every other day. R…

This early-phase trial tests whether a home-based morning light therapy program can help people with advanced melanoma who are receiving tumor-infiltrating lymphocyte (TIL) therapy. The light therapy is delivered through an iPad app and aims to improve the body's natural sleep-wa…

Researchers are testing whether a PET scan that highlights CD8 immune cells can show the best place to collect tumor-infiltrating lymphocytes (TILs) from patients with advanced melanoma. Participants receive standard TIL therapy and also undergo an extra tumor sample from the sit…

This study looks at whether clinical, pathological, and molecular features can predict how well people with metastatic melanoma respond to first-line immunotherapy. Researchers will collect and analyze data from about 200 patients treated at the European Institute of Oncology wit…

This early-phase study tests whether a low-dose immunotherapy injection directly into the tumor can activate the immune system as effectively as standard high-dose treatment through the veins, but with fewer side effects. About 18 adults with advanced melanoma will receive either…